Weight-loss drug before hernia surgery cuts complications in obese patients
NCT ID NCT07638592
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a 16-week weight-loss program using the drug tirzepatide before elective hernia surgery in 91 adults with obesity. Participants lost an average of 13.8% of their body weight, and all reached the target weight needed for surgery. Compared to a similar group who had surgery without the drug, those who took tirzepatide had fewer wound problems after the operation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERNIA ABDOMINAL WALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Francesco Pizza
Naples, 80131, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can a tailored lifestyle plan outsmart Obesity-Related health risks?
- Shake off the weight? vibration therapy put to the test against obesity
- Could a smartwatch and remote coaching cut incontinence after prostate surgery?
- New Self-Gripping mesh aims to reduce hernia recurrence in High-Risk patients